

Title (en)  
NOVEL TETRAVALENT BISPECIFIC ANTIBODY

Title (de)  
NEUER TETRAVALENTER BISPEZIFISCHER ANTIKÖRPER

Title (fr)  
NOUVEAU ANTICORPS BISPECIFIQUE TETRAVALENT

Publication  
**EP 1786918 A2 20070523 (EN)**

Application  
**EP 05773142 A 20050718**

Priority  
• US 2005025472 W 20050718  
• US 58868804 P 20040717

Abstract (en)  
[origin: WO2006020258A2] The invention is directed to novel tetravalent antibodies, which are preferably bi-specific. The tetravalent bispecific antibodies can be efficiently expressed in prokaryotic and eukaryotic cells, and are useful in therapeutic and diagnostic methods. The invention further describes administration of the antibodies, either alone or in combination with antiangiogenic or anti-neoplastic drugs to inhibit tumor growth and/or angiogenesis.

IPC 8 full level  
**A61K 39/395** (2006.01); **C07K 16/28** (2006.01); **C07K 16/46** (2006.01); **C12P 21/08** (2006.01)

CPC (source: EP)  
**A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 16/2863** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/622** (2013.01); **C07K 2317/626** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/77** (2013.01); **C07K 2317/92** (2013.01)

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR MK YU

DOCDB simple family (publication)  
**WO 2006020258 A2 20060223**; **WO 2006020258 A3 20061012**; EP 1786918 A2 20070523; EP 1786918 A4 20090211; JP 2008512352 A 20080424

DOCDB simple family (application)  
**US 2005025472 W 20050718**; EP 05773142 A 20050718; JP 2007521716 A 20050718